Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) Research & Development (2020 - 2025)

Historic Research & Development for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to $3.9 million.

  • Insight Molecular Diagnostics' Research & Development rose 3766.42% to $3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.3 million, marking a year-over-year increase of 2182.84%. This contributed to the annual value of $9.8 million for FY2024, which is 586.4% up from last year.
  • Latest data reveals that Insight Molecular Diagnostics reported Research & Development of $3.9 million as of Q3 2025, which was up 3766.42% from $3.3 million recorded in Q2 2025.
  • In the past 5 years, Insight Molecular Diagnostics' Research & Development ranged from a high of $5.1 million in Q1 2022 and a low of $1.4 million during Q4 2022
  • Moreover, its 5-year median value for Research & Development was $2.5 million (2021), whereas its average is $2.8 million.
  • As far as peak fluctuations go, Insight Molecular Diagnostics' Research & Development surged by 15505.56% in 2021, and later plummeted by 6998.48% in 2022.
  • Over the past 5 years, Insight Molecular Diagnostics' Research & Development (Quarter) stood at $4.6 million in 2021, then plummeted by 69.98% to $1.4 million in 2022, then soared by 84.83% to $2.5 million in 2023, then decreased by 11.39% to $2.3 million in 2024, then skyrocketed by 71.82% to $3.9 million in 2025.
  • Its Research & Development stands at $3.9 million for Q3 2025, versus $3.3 million for Q2 2025 and $2.9 million for Q1 2025.